An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

计划入组 139 人 · 首次发布于 2023 年 12 月 22 日

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

计划入组 188 人 · 首次发布于 2023 年 9 月 1 日

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

计划入组 113 人 · 首次发布于 2022 年 1 月 4 日

Veligrotug

VVZ-140

VVZ-2471

Sling Therapeutics Doses First Patients in Phase III ORBIT Trial of Oral Linsitinib for Thyroid Eye Disease

Veligrotug Shows Positive Phase 3 Results for Thyroid Eye Disease

Viridian's Veligrotug Shows Promise in Phase 3 Trial for Chronic Thyroid Eye Disease